| PERIOD ENDING | 31-Mar-09 | | Total Revenue | 97,555 | | Cost of Revenue | 72,880 | | | Gross Profit | 24,675 | | | Operating Expenses | | Research Development | 24,807 | | Selling General and Administrative | 19,309 | | Non Recurring |
-
| | Others | 1,468 | | | | Total Operating Expenses |
-
| | | | Operating Income or Loss | (20,909) | | | Income from Continuing Operations | | Total Other Income/Expenses Net | 12,830 | | Earnings Before Interest And Taxes | (8,080) | | Interest Expense | 1,505 | | Income Before Tax | (9,584) | | Income Tax Expense | 5,221 | | Minority Interest |
-
| | | | Net Income From Continuing Ops | (18,185) | | | Non-recurring Events | | Discontinued Operations |
-
| | Extraordinary Items |
-
| | Effect Of Accounting Changes |
-
| | Other Items |
-
| | | | Net Income | (18,185) | | Preferred Stock And Other Adjustments |
-
| | | Net Income Applicable To Common Shares | ($18,185) |
|
0.31% Nasdaq 
0.05%
Income Statement
